STIM · Neuronetics, Inc.
$2.34
-0.02 (-0.85%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, substantial doubt exists about the Company's ability to continue as a going concern. Actions within the Company's control to meet its minimum revenue covenant include improvements to its revenue cycle management, introducing new treatment options at its clinic locations and pursuing new strategies within its NeuroStar business to accelerate sales growth and optimize its product mix. The Company's ability to meet its liquidity needs, including meeting future revenue and liquidity covenants, is dependent on growth in existing and acquired product and service lines and the realization of synergies related to its acquisition of Greenbrook. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 11, 2026
Market Cap
$208.78M
Shares
76.20M
Volume · Sep 30
624.79K
Avg daily vol (3M)
2.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.34
Open$2.36
Day$2.34–2.42
52W close$1.18–3.30
Avg vol 30d1.2M
Short int6.2M · 8.1% float · 3.7d
Short vol16%
Last earningsAug 11, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 14, 2026
Est · unconfirmed
· in 6 wks
filed Aug 11, 2026
call held May 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$155.10M
Trailing 12 months
Net income (TTM)
−$30.42M
Trailing 12 months
Revenue growth YoY
+9.1%
Year over year
Operating margin
-14.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.5%
Year over year · more shares
Price change (1Y)
-11.3%
Trailing year
Short interest
8.1%
Latest settlement · 3.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
−12%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
55%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+70%
trailing
YTD return
+70%
this year
Relative strength
+57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$106.5K over 90 days · 0% sells
Short interest
Falling
8.15% of float · ▼ -6.9% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+31%
Y/Y
Gross margin
137%
expanding
EPS growth
+57%
Y/Y
Balance sheet
$37.7M
net debt
Quant / Vol
risk profile
Volatility
116%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
full year 2026
Total revenue
Initiated
$160M – $164M
prior FY $149.16M
midpoint +8.6% Y/Y
Gross margin
Initiated
48% – 50%
FY 2026
Cash Flow from Operations and Investing
Initiated
$-14.5M – $-10.5M
Guided vs delivered
· last 8 settled
Total worldwide revenue
third quarter of 2024
guided $18.5M – $19.5M
$18.53M
In line
Total worldwide revenue
full year 2024
guided $78M – $80M
$74.89M
Miss −5.2%
Total worldwide revenue
second quarter of 2024
guided $18M – $19M
$16.45M
Miss −11.1%
Total revenue
full year 2023
guided $70M – $72M
$71.35M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
55%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-13% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$106.5K over 90 days · 0% sells
Short interest
Falling
8.15% of float · ▼ -6.9% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 55%
Range high $3
vs 200-day avg +29%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$6.33M | Six months ended June 30 | — |
| EBITDA non-GAAP | -$9.55M | Six months ended June 30 | — |
| Net cash used in operations and investing | $1.4M | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STIM
this stock
Neuronetics, Inc.
|
$208.78M | +69.6% | +30.5% | — | 8.1% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STIM | -18.8% | -17.6% | +69.6% | -17.6% | +69.6% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -18.1% | -17.7% | +57.4% | -17.0% | +57.7% |